These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27926889)

  • 1. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
    Meyer RJ
    Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin and antidiabetic agents -- the old and the new.
    Golembiewski J
    J Perianesth Nurs; 2006 Apr; 21(2):131-4. PubMed ID: 16600835
    [No Abstract]   [Full Text] [Related]  

  • 3. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 5. A patient's opinion of unmet need.
    Hernandez M; Mehr SR
    Am J Manag Care; 2014 May; 20(8 Spec No.):E16. PubMed ID: 25617936
    [No Abstract]   [Full Text] [Related]  

  • 6. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate approaches for pediatric type 1 diabetes drug development and potential regulatory approval: a perspective.
    Turner JR; Close KL; Fleming GA; Wherrett DK; DiMeglio LA
    Diabetes Care; 2015 Oct; 38(10):1986-91. PubMed ID: 26404928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Mol PGM; Thompson A; Heerspink HJL; Leufkens HGM
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):19-23. PubMed ID: 30294953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled insulin--a new delivery for an old drug.
    Fantasia HC
    Nurs Womens Health; 2015; 19(1):67-70. PubMed ID: 25690817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide: FDA wants more.
    Diabetes Obes Metab; 2001 Oct; 3(5):386. PubMed ID: 11710342
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.
    Joffe HV; Parks MH; Temple R
    Rev Endocr Metab Disord; 2010 Mar; 11(1):21-30. PubMed ID: 20195772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA approves nateglinide for treatment of type 2 diabetes.
    Lieder TR
    Am J Health Syst Pharm; 2001 Feb; 58(4):285, 288. PubMed ID: 11225164
    [No Abstract]   [Full Text] [Related]  

  • 15. US FDA approves three new drugs for Type 2 diabetes.
    Bond T
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosiglitazone approved for treatment of type 2 diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
    [No Abstract]   [Full Text] [Related]  

  • 17. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
    Simmons K; Michels AW
    Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking the appraisal and approval of drugs for type 2 diabetes.
    Naci H; Lehman R; Wouters OJ; Goldacre B; Yudkin JS
    BMJ; 2015 Oct; 351():h5260. PubMed ID: 26452524
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approves saxagliptin for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
    [No Abstract]   [Full Text] [Related]  

  • 20. New technologies and therapies in the management of diabetes.
    Triplitt CL
    Am J Manag Care; 2007 Apr; 13 Suppl 2():S47-54. PubMed ID: 17417933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.